BR100 Increased By (0.85%)
BR30 Increased By (0.42%)
KSE100 Increased By (0.87%)
KSE30 Increased By (0.83%)
AGHA 6.03 Increased By ▲ 0.01 (0.17%)
BECO 3.86 Increased By ▲ 0.05 (1.31%)
BML 61.00 Increased By ▲ 4.56 (8.08%)
BOP 28.09 Decreased By ▼ -0.01 (-0.04%)
CNERGY 11.74 Decreased By ▼ -0.54 (-4.4%)
CSIL 5.30 Increased By ▲ 0.01 (0.19%)
FCCL 54.46 Increased By ▲ 0.65 (1.21%)
FFL 13.07 Increased By ▲ 0.27 (2.11%)
FNEL 1.11 Decreased By ▼ -0.01 (-0.89%)
KEL 5.63 Decreased By ▼ -0.01 (-0.18%)
KOSM 5.34 Decreased By ▼ -0.04 (-0.74%)
LOTCHEM 23.83 Increased By ▲ 0.28 (1.19%)
MLCF 92.98 Increased By ▲ 1.02 (1.11%)
NBP 163.20 Increased By ▲ 0.96 (0.59%)
NCPL 48.27 Decreased By ▼ -0.64 (-1.31%)
NPL 49.71 Decreased By ▼ -0.80 (-1.58%)
OGDC 303.63 Increased By ▲ 1.95 (0.65%)
PACE 8.97 Decreased By ▼ -0.16 (-1.75%)
PAEL 31.91 Increased By ▲ 0.10 (0.31%)
PIBTL 12.74 Decreased By ▼ -0.04 (-0.31%)
PPL 212.91 Increased By ▲ 0.85 (0.4%)
PRL 84.34 Decreased By ▼ -2.92 (-3.35%)
PTC 44.99 Increased By ▲ 1.03 (2.34%)
SSGC 22.83 Decreased By ▼ -0.03 (-0.13%)
TBL 8.88 Decreased By ▼ -0.03 (-0.34%)
TELE 6.50 Increased By ▲ 0.06 (0.93%)
TPL 24.26 Increased By ▲ 0.17 (0.71%)
TPLP 11.99 Decreased By ▼ -0.17 (-1.4%)
TREET 23.14 Decreased By ▼ -0.36 (-1.53%)
TRG 51.47 Decreased By ▼ -0.40 (-0.77%)
World Print edition: 2021-03-13

WHO approves J&J vaccine

Published Updated
By

GENEVA: The World Health Organization on Friday approved Johnson & Johnson's Covid-19 vaccine, after already authorising the jabs made by Pfizer-BioNTech and Oxford-AstraZeneca.

"Every new, safe and effective tool against Covid-19 is another step closer to controlling the pandemic," WHO chief Tedros Adhanom Ghebreyesus said in a statement.

The news comes after the single-dose jab won approval from the European Union on Thursday.

It has also received the green light from regulators in the United States, Canada and South Africa.

The World Health Organization said the J&J jab had been granted an "emergency use listing" which assesses the suitability of new health products during public health emergencies, and is quicker than the regular licensing system.

Comments

Comments are closed for this article.